2026-04-25T14:49:25Z
https://www.pub.unibl.org/oai
oai:pub.unibl.org:28928
2025-12-19T04:43:49Z
Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety.
https://www.unibl.org/sr-lat/fis/zaposlen/3512-sasa-jungic
/unibl/author/Gordana Kecman Malčić
/unibl/author/Ivanka Rakita
/unibl/author/Dušan Jovanović
https://www.unibl.org/sr-lat/fis/zaposlen/3346-radoslav-gajanin
/unibl/author/Zdravko Marić
/unibl/author/Tubić Biljana
https://www.unibl.org/sr-lat/fis/zaposlen/3371-zdenka-gojkovic
2014-06
Conference Paper
text
68
68
/unibl/sci/idNaucniRad:7053
https://med.unibl.org
ESMO 16th World Congress on Gastrointestinal Cancer
Annals of Oncology 2014; 25 (Supplement 2):
Annals of Oncology 2014; 25 (Supplement 2):
http://annonc.oxfordjournals.org/search?submit=yes&tocsectionid=symposium%20article&volume=25&issue=suppl%202
С. Јунгић, G. Kecman Malčić, И. Ракита, D. Jovanović, R. Gajanin, З. Марић, T. Biljana, З. Гојковић, Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety., Annals of Oncology 2014; 25 (Supplement 2):, pp. 68 - 68, Jun, 2014